Buckingham Strategic Partners Sells 2,109 Shares of Merck & Co., Inc. (NYSE:MRK)

Buckingham Strategic Partners trimmed its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 30.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,826 shares of the company’s stock after selling 2,109 shares during the quarter. Buckingham Strategic Partners’ holdings in Merck & Co., Inc. were worth $395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bromfield Sneider Wealth Advisors bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $79,000. Hikari Power Ltd lifted its holdings in shares of Merck & Co., Inc. by 5.0% during the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock valued at $1,939,000 after buying an additional 1,130 shares during the period. ACG Wealth lifted its holdings in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock valued at $1,110,000 after buying an additional 722 shares during the period. Mascoma Wealth Management LLC raised its holdings in Merck & Co., Inc. by 36.4% in the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock worth $76,000 after purchasing an additional 247 shares during the period. Finally, WealthBridge Investment Counsel Inc. raised its holdings in Merck & Co., Inc. by 4.1% in the 1st quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company’s stock worth $7,206,000 after purchasing an additional 3,475 shares during the period. 72.88% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Down 0.0 %

Shares of NYSE:MRK opened at $90.59 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $95.72. The company has a 50-day moving average price of $90.11 and a 200 day moving average price of $85.89. The company has a market cap of $229.49 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 1.22 and a beta of 0.32.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.18. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. During the same quarter last year, the firm earned $1.31 EPS. The firm’s revenue for the quarter was up 28.0% compared to the same quarter last year. As a group, equities research analysts predict that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.05%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is currently 42.27%.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. UBS Group raised their target price on Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a report on Monday, July 18th. Cowen raised their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Morgan Stanley increased their price target on Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Daiwa Capital Markets upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price target for the stock from $89.00 to $102.00 in a research note on Wednesday, July 6th. Finally, Cowen increased their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $97.44.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.